Skip to main content
. 2021 May 20;118(21):e2103180118. doi: 10.1073/pnas.2103180118

Fig. 5.

Fig. 5.

PDZ1i suppresses IL-1β expression and regulates primary tumor growth. (A) Following implantation of 4T1-Luc cells in the fourth mammary fat pad, mice were divided into two groups, vehicle control and PDZ1i, as described in Materials and Methods. Treatment started after 12 h. Tumors were excised on day 14 d and weighed. The average values from five mice are presented. (B) Tumor lysates were prepared and analyzed for IL-1β using ELISA. (C) Orthotopically implanted tumor-bearing mice received a single dose of DMSO or PDZ1i intraperitoneally 6 h after intratumoral injection of recombinant IL-1β (rIL-1β). Tumors were excised after 3 h of rIL-1β injection and analyzed for the accumulation of G-MDSCs. (D) Indicated cell lines were implanted in the fourth mammary fat pad and received DMSO or PDZ1i for 2 wk (injected intraperitoneally every alternate day, total of six injections). Tumor weight was measured and the average value of each group is plotted. (E) Tumors were analyzed for G-MDSCs by FACS and the average values are presented. *P < 0.05 is considered as statistically significant.